Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

Also called NCT03103256

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 106 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03103256
Other papers using this trial's data
  • A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension Journal of clinical hypertension (Greenwich, Conn.), 2020-02 DOI, PubMed 32003938, PMC8029832 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03103256. Randomized; double masking; primary purpose treatment. Start 2017-05-17 (actual); primary completion 2018-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Efficacy and Safety of YHP1701
Condition
Hypertension and Hyperlipidemia
Intervention (Drug)
YHP1701
Intervention (Drug)
YHR1703
Intervention (Drug)
YHR1704
Lead sponsor
Yuhan Corporation (class: industry)

Record details

Record id
cardio:ct-nct03103256
Content hash
764535d665daa8de8feb38b08067643553c86b2e74d4c324fc595867c8a6057b